Chiromics, LLC

Merck Sharp + Dohme Corp.

Michael David VanHeyst

James S Harvey

Elizabeth Gerig Rowley

Joel Francis Austin

Christophe Lamarque-Lacoste

Ian M Bell

Ashok Arasappan

Jian Liu

James J Perkins

Jason M Cox

Christopher S Burgey

Mark E Layton

Hong Liu

Christopher James Bungard

Michael J Kelly, Iii

Zhe Wu

Akshay A Shah

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Na1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Na1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

2-oxoimidazolidine-4-carboxamides as NA1.8 inhibitors

Disclosed herein are compounds, of the class of amine-bearing heterocycles, which act as positive allosteric modulators and silent allosteric modulators of the mu opioid receptor. These compounds are useful for the treatment of pain, drug addiction, and other CNS derived maladies that are controlled directly or indirectly by activation of the mu opioid receptor. Methods for making and using the allosteric modulators disclosed herein are also provided.

Allosteric modulators of the mu opioid receptor

Growing community of inventors

Harleysville, PA, United States of America

Michael David VanHeyst